See any site problems? Let us know if something looks wrong or isn't working. Click here Report a problem
The information contained in Onco'Zine - The International Cancer Network is generally technical in nature and intended for Healthcare Professionals.
Contribute to Onco'Zine - The International Oncology Network by submitting an idea or draft articles to the editor
Are you interested in becoming an Editorial Board member for Onco'Zine - The International Oncology Network and helping to maintain the editorial standards and ethos of this growing journal? To volunteer as an Associate Editor or Contributing Authors, please simply contact us Please enclosing a summary of your research interests and relevant expertise within Oncology and Hematology. We look forward to hearing from you.
Researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, Princess Margaret Cancer Center, the University of Toronto, Harvard Medical School and Oxford University have identified a new signaling pathway that helps cancer cells cope with the lack of oxygen found inside tumors. These are the results of a study published in Nature Cell Biology on June 20, 2016.
Quality of life—it’s a term that gets thrown around a lot when people are sick. The phrase refers to how well you can live the life you want and how happy you are during it. For patients with life-threatening conditions like colorectal cancer, it’s common to wonder, “What will I be like after my chemotherapy or radiation are over?” It’s a question that can be hard to answer and the truth is that life after cancer can look very different from patient to patient. How your life changes will…Continue
In a phase II study, IMvigor 210, atezolizumab (Tecentriq™; Genentech, a member of the Roche Group)shrank tumors (objective response rate, ORR) in 24% (n=28) of people with locally advanced or metastatic urothelial carcinoma (mUC) who have not received a prior treatment (first-line) and who were ineligible for cisplatin-based chemotherapy. Of those people who responded, 75% (n=21) continued to respond to treatment and the median duration of response (DOR) had not been reached at the…Continue
Positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (iNHL). The study compared the efficacy and safety of obinutuzumab (Gazyva®; Genentech) plus chemotherapy (CHOP, CVP or bendamustine) followed by obinutuzumab alone, head-to-head with rituximab (…Continue
Researchers from the Okayama University in Japan report photoimmunotherapy to be effective against elusive gastric cancer cells following transduction with the gene that expresses the extracellular domain protein of HER2. The results are published in the February 2016 edition of the journal Small Molecule Therapeutics in February 2016.
“Gastric cancer is one of the most common malignancies worldwide, making it the third leading cause of cancer-related death,” explain…Continue
A new study supported by funding from the National Institutes of Health and the Yale Cancer Center sheds light on how melanoma cells change from benign to malignant, and how the complex interaction between the cells and their surrounding environment affects outcomes of the cancer.
The transition from the radial growth patterns of benign melanoma cells to the vertical patterns of malignant cells has long been a mystery to researchers. But a study from the lab of Andre Levchenko, the…Continue
Several drugs now being used to treat heart failure and atrial arrhythmia also show promise as DNA disruptors in cancer cells and could be readily repurposed as anticancer agents, according to a new study by Yale researchers which was supported by the National Institute of General Medical Sciences, CureSearch for Children’s Cancer, and the Yale Center for Molecular Discovery.
Cardiac glycosides, which are bioactive natural products found in certain plants and insects, aid in cardiac…Continue
Contributing Editors: Amit Kumar, Ph.D and Robert Berman
For nearly 45 years, the national dialogue, when it comes to cancers, has remained essentially the same. We have been racing for the cure, praying for the cure, searching for the cure, researching for the cure, raising money for the cure, funding the cure, and developing treatments for the cure. Curing cancer has become the “national cancer objective”.…Continue
Senior leaders from more than a dozen biopharmaceutical companies came together today with world-class academic clinicians from four leading cancer centers, representatives from oncology non-profits, the FDA, and other key stakeholder organizations to advance the most promising avenues for curing cancer: accelerating the development of investigational drug combination therapies of two or more investigational treatments which may hold great promise for cancer patients.